Adial Pharmaceuticals (ADIL) Q4 2025 earnings summary

Executive summary

• Achieved positive clinical results from the AD04-103 PK study, supporting regulatory strategy for AD04 targeting addiction disorders.

• Received favorable FDA feedback on in vitro bridging strategy and completed End-of-Phase 2 meeting, advancing toward Phase 3.

• Entered a collaboration framework with Molteni for exclusive commercialization of AD04 in Europe, with potential value up to $60 million.

• Regained compliance with Nasdaq minimum bid price requirements, resolving prior listing issues.

Financial highlights

• Cash and cash equivalents were $5.9 million as of December 31, 2025, up from $3.8 million at year-end 2024.

• Net loss for 2025 was $8.0 million, a significant improvement from $13.2 million in 2024, mainly due to lower R&D spending and absence of a one-time $4.5 million inducement expense.

• Research and development expenses decreased by 19% year-over-year, driven by lower clinical activity and compensation.

• General and administrative expenses increased by 2% year-over-year, primarily due to higher compensation.

Outlook and guidance

• Existing cash is expected to fund operations into the second half of 2026 based on current development plans.

• Planning a new Phase 3 clinical trial for AD04 in genetically targeted AUD patients.

• Potential for reduced late-stage development costs and accelerated timelines if FDA allows a single pivotal study for approval.